Search Results | Cancer Research | American Association for Cancer Research

1-20 of 84

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Abstract 1890: Development of the drug efficacy testing in ex vivo 3D cultures (DETECT) platform and its application to functional precision medicine in ovarian cancer

Emma Åkerlund, Greta Gudoityte, Elisabeth Moussaud Lamodiere, Joseph Carlson, Emelie Wallin, Josefin Fernebro, Olli Kallioniemi, Päivi Östling, Ulrika Joneborg, Brinton Seashore-Ludlow

Cancer Res (2022) 82 (12_Supplement): 1890.

DOI: https://doi.org/10.1158/1538-7445.AM2022-1890

Published: 15 June 2022

View article

Journal Articles

Abstract 4134: Stromal FAP expression is associated with MRI visibility and patient survival in prostate cancer

Teijo Pellinen, Kevin Smith, Sami Blom, Riku Turkki, Annabrita Hemmes, Katja Välimäki, Juho Eineluoto, Anu Kenttämies, Stig Nordling, Olli Kallioniemi, Antti Rannikko, Tuomas Mirtti

Cancer Res (2022) 82 (12_Supplement): 4134.

DOI: https://doi.org/10.1158/1538-7445.AM2022-4134

Published: 15 June 2022

View article

Journal Articles

Abstract 458: Precision systems medicine in acute myeloid leukemia: real-time translation of tailored therapeutic opportunities arising from ex-vivo drug sensitivity testing and molecular profiling

Cancer Res (2019) 79 (13_Supplement): 458.

DOI: https://doi.org/10.1158/1538-7445.AM2019-458

Published: 01 July 2019

View article

Journal Articles

Abstract 2945: Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling

Astrid Murumägi, Daniela Ungureanu, Suleiman Khan, Akira Hirasawa, Mariliina Arjama, Katja Välimäki, Piia Mikkonen, Wilhelmiina Niininen, Ashwini Kumar, Samuli Eldfors, Teijo Pellinen, Vilja Pietiäinen, Andrus Mägi, Riitta Koivisto-Korander, Johanna Tapper, Mikko Loukovaara, Tero Aittokallio, Ralf Bützow, Olli Kallioniemi

Cancer Res (2019) 79 (13_Supplement): 2945.

DOI: https://doi.org/10.1158/1538-7445.AM2019-2945

Published: 01 July 2019

View article

Journal Articles

Abstract 3899: Discovery and clinical implementation of individualized therapies in acute myeloid leukemia based on ex vivo drug sensitivity testing and multi-omics profiling

Cancer Res (2018) 78 (13_Supplement): 3899.

DOI: https://doi.org/10.1158/1538-7445.AM2018-3899

Published: 01 July 2018

View article

Journal Articles

Abstract 286: Transcriptomic features predicting drug sensitivity and resistance in acute myeloid leukemia

Ashwini Kumar, Disha Malani, Bhagwan Yadav, Mika Kontro, Matti Kankainen, Swapnil Potdar, Simon Anders, Kimmo Porkka, Olli Kallioniemi Kallioniemi, Caroline Heckman

Cancer Res (2018) 78 (13_Supplement): 286.

DOI: https://doi.org/10.1158/1538-7445.AM2018-286

Published: 01 July 2018

View article

Journal Articles

Abstract 2199: Establishment and high-throughput drug testing of multiple patient-derived cells from each renal cancer; intratumor heterogeneity of drug response and implications for precision medicine

Khalid Saeed, Poojitha Ojamies, Teijo Pellinen, Samuli Eldfors, Riku Turkki, Johan Lundin, Harry Nisen, Petrus Järvinen, Kimmo Taari, Taija af Hällström, Antti Rannikko, Tuomas Mirtti, Olli Kallioniemi, Päivi Östling

Cancer Res (2018) 78 (13_Supplement): 2199.

DOI: https://doi.org/10.1158/1538-7445.AM2018-2199

Published: 01 July 2018

View article

Journal Articles

Abstract 5029: Precision cancer medicine based on 3D drug profiling of patient-derived cancer cell spheroid models

Piia Mikkonen, Laura Turunen, Lauri Paasonen, Swapnil Potdar, Lassi Paavolainen, Astrid Murumägi, Olli Kallioniemi, Vilja M. Pietiäinen

Cancer Res (2018) 78 (13_Supplement): 5029.

DOI: https://doi.org/10.1158/1538-7445.AM2018-5029

Published: 01 July 2018

View article

Journal Articles

Abstract 5302: Phenotypic heterogeneity of patient-derived tumor cells visualized by unsupervised analysis in cell-based personalized drug testing

Riku Turkki, Lassi Paavolainen, Piia Mikkonen, Päivi Östling, Peter Horvath, Vilja Pietiäinen, Olli Kallioniemi

Cancer Res (2018) 78 (13_Supplement): 5302.

DOI: https://doi.org/10.1158/1538-7445.AM2018-5302

Published: 01 July 2018

View article

Journal Articles

Abstract 410: Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells

Astrid Murumägi, Akira Hirasawa, Suleiman Khan, Daniela Ungureanu, Mariliina Arjama, Teijo Pellinen, Samuli Eldfors, Riitta Koivisto-Korander, Arto Leminen, Ralf Bützow, Tero Aittokallio, Olli Kallioniemi

Cancer Res (2017) 77 (13_Supplement): 410.

DOI: https://doi.org/10.1158/1538-7445.AM2017-410

Published: 01 July 2017

View article

Journal Articles

Abstract 3854: Precision medicine approach: analysis of renal cancer patient-derived cells with phenomics, genomics and drug sensitivity profiling

Vilja M. Pietiäinen, Piia Mikkonen, Khalid Saeed, Lassi Paavolainen, Teijo Pellinen, Swapnil Potdar, John Mpindi, Harry Nisén, Antti Rannikko, Tuomas Mirtti, Peter Horvath, Päivi Östling, Olli Kallioniemi

Cancer Res (2017) 77 (13_Supplement): 3854.

DOI: https://doi.org/10.1158/1538-7445.AM2017-3854

Published: 01 July 2017

View article

Journal Articles

Abstract 3122: Pharmacogenomic profiling to identify novel therapeutic strategies in colorectal cancer

Jarle Bruun, Peter W. Eide, Kushtrim Kryeziu, Anita Sveen, Astrid Murumägi, Matthias Kolberg, Mariliina Arjama, Olli Kallioniemi, Ragnhild A. Lothe

Cancer Res (2017) 77 (13_Supplement): 3122.

DOI: https://doi.org/10.1158/1538-7445.AM2017-3122

Published: 01 July 2017

View article

Journal Articles

Abstract 424: Landscape of somatic mutations in drug-resistant acute myeloid leukemia

Samuli Eldfors, Mika Kontro, Yevhen Akimov, Olli Kallioniemi, Kimmo Porkka, Caroline Heckman

Cancer Res (2017) 77 (13_Supplement): 424.

DOI: https://doi.org/10.1158/1538-7445.AM2017-424

Published: 01 July 2017

View article

Journal Articles

Abstract 5732: PI3K/Akt activity regulates androgen receptor expression and predicts poor clinical outcome in non-metastatic hormone-naïve prostate cancer

Sami Blom, Petra Mäki-Teeri, Andrew Erickson, Lassi Paavolainen, Tuomas Mirtti, Antti Rannikko, Swapnil Potdar, Päivi Östling, Wytske van Weerden, Olli Kallioniemi, Teijo Pellinen

Cancer Res (2017) 77 (13_Supplement): 5732.

DOI: https://doi.org/10.1158/1538-7445.AM2017-5732

Published: 01 July 2017

View article

Journal Articles

Abstract 1517: Impact of poly-A and ribo-depletion RNA-seq library construction protocols on transcriptomic analysis of samples from patients with haematological malignancies

Ashwini Kumar, Matti Kankainen, Alun Parsons, Olli Kallioniemi, Pirkko Mattila, Caroline Heckman

Cancer Res (2016) 76 (14_Supplement): 1517.

DOI: https://doi.org/10.1158/1538-7445.AM2016-1517

Published: 15 July 2016

View article

Journal Articles

Abstract 2378: Responses of AML patients to tailored drug regimens: monitoring cancer subclones by ultra-deep resequencing

Poojitha N Ojamies, Mika Kontro, Henrik Edgren, Pekka Ellonen, Sonja Lagstrom, Henrikki Almusa, Timo Miettinen, Samuli Eldfors, David Tamborero, Krister Wennerberg, Caroline Heckman, Kimmo Porkka, Maija Wolf, Olli Kallioniemi

Cancer Res (2016) 76 (14_Supplement): 2378.

DOI: https://doi.org/10.1158/1538-7445.AM2016-2378

Published: 15 July 2016

View article

Journal Articles

Abstract 2935: Systematic drug testing and RNA-sequencing of tamoxifen resistant breast cancer cell lines

Susanne Hultsch, Sara Kangaspeska, Matti Kankainen, Vilja Pietiäinen, Olli Kallioniemi

Cancer Res (2016) 76 (14_Supplement): 2935.

DOI: https://doi.org/10.1158/1538-7445.AM2016-2935

Published: 15 July 2016

View article

Journal Articles

Abstract 4679: Acquisition of cytarabine resistance leads to increased glucocorticoid sensitivity in AML

Disha Malani, Astrid Murumägi, Bhagwan Yadav, Mika Kontro, Samuli Eldfors, Ashwini Kumar, Krister Wennerberg, Caroline Heckman, Kimmo Porkka, Maija Wolf, Tero Aittokallio, Olli Kallioniemi

Cancer Res (2016) 76 (14_Supplement): 4679.

DOI: https://doi.org/10.1158/1538-7445.AM2016-4679

Published: 15 July 2016

View article

Journal Articles

Abstract 207: Caveolin-1 drives oncogenic TGFβ effects in prostate cancer: in vitro mechanistic insights integrated with systems pathology visualization in primary tumor samples

Teijo Pellinen, Sami Blom, Sara Sanches, Katja Välimäki, John-Patrick Mpindi, Antti Rannikko, Raffaele Strippoli, Maria Montoya, Hind Azegrouz, Tuomas Mirtti, Miguel del Pozo, Olli Kallioniemi

Cancer Res (2015) 75 (15_Supplement): 207.

DOI: https://doi.org/10.1158/1538-7445.AM2015-207

Published: 01 August 2015

View article

Journal Articles

Abstract 676: Axitinib targets gatekeeper-mutant BCR-ABL1(T315I)-driven leukemia in a distinct and selective fashion

Tea Pemovska, Eric Johnson, Mika Kontro, Gretchen A. Repasky, Jeffrey Chen, Peter Wells, Ciarán N. Cronin, Michele McTigue, Olli Kallioniemi, Kimmo Porkka, Brion W. Murray, Krister Wennerberg

Cancer Res (2015) 75 (15_Supplement): 676.

DOI: https://doi.org/10.1158/1538-7445.AM2015-676

Published: 01 August 2015

View article

2 3 4 5

NARROW

Abstract 1890: Development of the drug efficacy testing in ex vivo 3D cultures (DETECT) platform and its application to functional precision medicine in ovarian cancer

Abstract 4134: Stromal FAP expression is associated with MRI visibility and patient survival in prostate cancer

Abstract 458: Precision systems medicine in acute myeloid leukemia: real-time translation of tailored therapeutic opportunities arising from ex-vivo drug sensitivity testing and molecular profiling

Abstract 2945: Clinical implementation of precision systems oncology in the treatment of ovarian cancer based on ex-vivo drug testing and molecular profiling

Abstract 3899: Discovery and clinical implementation of individualized therapies in acute myeloid leukemia based on ex vivo drug sensitivity testing and multi-omics profiling

Abstract 286: Transcriptomic features predicting drug sensitivity and resistance in acute myeloid leukemia

Abstract 2199: Establishment and high-throughput drug testing of multiple patient-derived cells from each renal cancer; intratumor heterogeneity of drug response and implications for precision medicine

Abstract 5029: Precision cancer medicine based on 3D drug profiling of patient-derived cancer cell spheroid models

Abstract 5302: Phenotypic heterogeneity of patient-derived tumor cells visualized by unsupervised analysis in cell-based personalized drug testing

Abstract 410: Identifying ovarian cancer specific targeted drugs using high-throughput drug sensitivity profiles of primary cancer cells

Abstract 3854: Precision medicine approach: analysis of renal cancer patient-derived cells with phenomics, genomics and drug sensitivity profiling

Abstract 3122: Pharmacogenomic profiling to identify novel therapeutic strategies in colorectal cancer

Abstract 424: Landscape of somatic mutations in drug-resistant acute myeloid leukemia

Abstract 5732: PI3K/Akt activity regulates androgen receptor expression and predicts poor clinical outcome in non-metastatic hormone-naïve prostate cancer

Abstract 1517: Impact of poly-A and ribo-depletion RNA-seq library construction protocols on transcriptomic analysis of samples from patients with haematological malignancies

Abstract 2378: Responses of AML patients to tailored drug regimens: monitoring cancer subclones by ultra-deep resequencing

Abstract 2935: Systematic drug testing and RNA-sequencing of tamoxifen resistant breast cancer cell lines

Abstract 4679: Acquisition of cytarabine resistance leads to increased glucocorticoid sensitivity in AML

Abstract 207: Caveolin-1 drives oncogenic TGFβ effects in prostate cancer: in vitro mechanistic insights integrated with systems pathology visualization in primary tumor samples

Abstract 676: Axitinib targets gatekeeper-mutant BCR-ABL1(T315I)-driven leukemia in a distinct and selective fashion

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only